期刊文献+

七叶皂苷钠对胆管癌细胞株Hccc9810增殖和凋亡的影响 被引量:4

Effects of sodium aescinate on proliferation and apoptosis of human cholandiocarcinoma Hccc9810 cell line
原文传递
导出
摘要 目的观察七叶皂苷钠对人胆管癌细胞株Hccc9810增殖和凋亡的影响。方法运用细胞染色、噻唑蓝(MTT)比色法、流式细胞术和实时荧光定量聚合酶链反应(PCR)等技术观察不同浓度(、10、20、40μmol/L)七叶皂苷钠对胆管癌细胞增殖、细胞周期和凋亡的影响。结果七叶皂苷钠呈时间剂量依赖性抑制胆管癌细胞Hccc9810的增殖,其24、48、72h的50%抑制浓度(IC50)分别为:(45.34±2.12)、(33.00±1.92)、(25.00±1.65)μmol/L;G1期比例从(49.49±1.22)%上升到(70.20±1.52)%;胆管癌细胞形态发生典型凋亡特征性改变,凋亡率随浓度的升高从20.54%上升到62.56%,差异均有统计学意义(P〈0.05)。结论七叶皂苷钠通过阻滞细胞周期和诱导细胞凋亡而抑制胆管癌细胞Hccc9810增殖。 Objective To investigate the effects of sodium aescinate on the proliferation and apoptosis of cholangiocarcinoma Hece9810 cell line. Methods The effects of sodium aeseinate (0,10, 20, 40μmol/L) on cell growth, cycle and apoptosis were investigated by methyl thiazol tetrazolium (MTT) assay, flow cytometry, and fluorescence microscopy. Results Sodium aescinate inhibited cholangiocareinoma cell growth in a dose- and time-dependent manner, and its half-inhibitory concentration ( IC50 ) for 24 h, 48 h, and 72 h was (45.34 ±2. 12), (33.00 ± 1.92) and (25.00 ± 1.65) μmol/L respectively. The proportion of cells in G1 phase was increased from (49.49 ± 1.22) % to (70. 20 ±1.52) %. The apoptosis rate was increased from 20. 54% to 62. 56% (P 〈 0. 05 ). Conclusion Sodium aeseinate exhibited its anticarcinoma effect probably through regulating cell cycle and inducing cell apoptosis.
出处 《中华实验外科杂志》 CAS CSCD 北大核心 2011年第11期1835-1837,共3页 Chinese Journal of Experimental Surgery
关键词 七叶皂苷钠 增殖 胆管癌 Sodium aeseinate Proliferation Cholangioeareinoma
  • 相关文献

参考文献3

二级参考文献34

共引文献20

同被引文献22

  • 1Kim AR, Balls FM, Widemann BC. Sor- afenib and sunitinib. Oncologist, 2009, 14:800-805.
  • 2Huether A,Hopfner M,Baradari V,et al. Sor- afenib alone or as combination therapy for growth control of cholangiocarcinoma. Bio- chem Pharmaco! ,2007,73 : 1308-1317.
  • 3Blechacz BRA, Smoot RL, Bronk SF, et al. Sorafenib inhibits signal transducer and activator of transcription - 3 signaling in cholangi cells by activating the phosphatase shatterproof 2. Hepatology 2009,50 : 1861-1870.
  • 4Bengala C, Bertolini F, Malavasi N, et al. Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial. Br J Cancer, 2009,102 : 68 -72.
  • 5EI-Khoueiry AB, Rankin CJ, Ben-Josef E, et al. SWOG 0514 : a phase II study of sor- afenib in patients with unresectable or me- tastatic gallbladder carcinoma and cholan- giocarcinoma. Invest New Drugs, 2011, 30 : 1646-1651.
  • 6Rosato RR, Almenara JA, Coe S, et al. The multikinase inhibitor sorafenib potentiates TRAIL lethality in human leukemia cells in association with Mcl-1 and cFLIPL down-regulation. Cancer Res, 2007, 67 : 9490-9500.
  • 7Sirtori CR. Aescin:pharmacology,pharmacokinetics and therapeutic profile[J].{H}PHARMACOLOGICAL RESEARCH,2001,(03):183-193.
  • 8Naito AT,Okada S,Minamino T. Promotion of CHIPmediated p53 degradation protects the heart from ischemic injury[J].{H}CIRCULATION RESEARCH,2010,(11):1692-1702.
  • 9Ulrich CM,Bigler J,Potter JD. Non-steroidal anti-inflammatory drugs for cancer prevention:promise,perils and pharmacogenetics[J].Nat Rev Cance,2006,(02):130-140.
  • 10Kuang YF,Chen YH. Induction of apoptosis in a non small cell human lung cancer cell line by isothiocyanates is associated with p53 and p21[J].{H}Food and Chemical Toxicology,2004,(10):1711-1718.

引证文献4

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部